Aarkstore -Glycoprotein Inhibitors -Pipeline Insights, 2014

1
Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/73733/glycoprotein-iib-iiia-gpiibiiia-inhibitors
  -pipeline-insights-2014

2
Summary

• DelveInsights,Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA). A
  key objective of the report is to establish the
  understanding for all the pipeline drugs that
  fall under Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors. This report provides information on
  the therapeutic development based on the
  Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
  dealing with mechanism of action, comparative
  analysis at various stages covering Filed, Phase
  III, Phase II, Phase I, IND filed, Preclinical,
  Discovery and unknown stages, therapeutics
  assessment by monotherapy and combination
  products and molecule type drug information. The
  report also covers the companies information
  involved in the therapeutic development of the
  products. It also has highlighted the
  discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action. 

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Glycoprotein IIb-IIIa
  (GPIIb/IIIa) InhibitorsThe report provides
  pipeline products under drug profile section
  which includes product description, MOA,
  licensors collaborators, development partner
  and chemical informationCoverage of the
  Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
  pipeline on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for Glycoprotein
  IIb-IIIa (GPIIb/IIIa) Inhibitors and also provide
  company profilingThe report also gives the
  information of dormant and discontinued pipeline
  projects Pipeline products coverage based on
  various stages of development ranging from
  preregistration till discovery and undisclosed
  stages Provides pipeline assessment by
  monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors
• Identify the relationship between the drugs and
  use it for target finding, drug repurposing, and
  precision medicine.
• Devise corrective measures for pipeline projects
  by understanding Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors pipeline depth and focus
  of Indication therapeutics
• Developing strategic initiatives to support your
  drug development activities.
• Optimize your portfolio and keep you in touch
  with the rapidly changing pharmaceutical markets,
  and make the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies
• Modify the therapeutic portfolio by identifying
  discontinued projects and understanding the
  factors that drove them from pipeline
• Gaining a Full Picture of the Competitive
  Landscape for Evidence based Decision

7
Table of Content

• Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
  OverviewGlycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Disease AssociatedGlycoprotein
  IIb-IIIa (GPIIb/IIIa) Inhibitors Pipeline
  TherapeuticsGlycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Therapeutics under Development by
  Companies Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Late Stage Products (Filed and Phase
  III)Comparative Analysis Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors Mid Clinical Stage
  Products (Phase II)Comparative
  Analysis Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Early Clinical Stage Products (Phase I
  and IND Filed)Comparative Analysis Glycoprotein
  IIb-IIIa (GPIIb/IIIa) Inhibitors Discovery and
  Pre-Clinical Stage Products Comparative
  Analysis Drug Candidate Profiles

8
Table of Content

• Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
  Therapeutics Assessment Assessment by
  Monotherapy Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Discontinued Products Glycoprotein
  IIb-IIIa (GPIIb/IIIa) Inhibitors Dormant
  ProductsCompanies Involved in Therapeutics
  Development for Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors Appendix Methodology Co
  ntact Us Disclaimer

9
List of Tables

• Number of Products under Development for
  Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors by
  Therapy Area, 2014Number of Products under
  Development for Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors, 2014Number of Products
  under Development by Companies Comparative
  Analysis by Late Clinical Stage Products (Filed
  and Phase III), 2014Comparative Analysis Mid
  Clinical Stage Products (Phase II),
  2014Comparative Analysis Early Clinical Stage
  Products (Phase I and IND Filed),
  2014Comparative Analysis Discovery and
  Pre-Clinical Stage Products, 2014Drug Candidates
  ProfilesGlycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Assessment by Monotherapy Products 

10
List of Tables

• Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
  Assessment by Combination Products Glycoprotein
  IIb-IIIa (GPIIb/IIIa) Inhibitors Assessment by
  Route of Administration Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors Assessment by Stage and
  Route of Administration Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors Assessment by Molecule
  Type Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Assessment by Stage and Molecule
  Type Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Therapeutics Discontinued
  Products Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Therapeutics Dormant ProductsProducts
  under Development by Companies, 2014

11
List of Figures

• Number of Products under Development for
  Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors by
  Therapy Area, 2014Number of Products under
  Development for Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors, 2014Late Clinical Stage
  Products (Filed and Phase III), 2014Mid Clinical
  Stage Products (Phase II), 2014Early Clinical
  Stage Products (Phase I and IND Filed),
  2014Discovery and Pre-Clinical Stage Products,
  2014Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Assessment by Monotherapy
  Products Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Assessment by Combination
  Products Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Assessment by Route of
  Administration Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors Assessment by Stage and
  Route of Administration Glycoprotein IIb-IIIa
  (GPIIb/IIIa) Inhibitors Assessment by Molecule
  Type Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors Assessment by Stage and Molecule Type

12
Related Reports

• 2015 Worldwide Medical Laboratories
  Industry-Industry Market Report
• 2015 Worldwide Pharmaceutical Preparation Mfg.
  Industry-Industry Market Report
• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Glycoprotein IIb-IIIa (GPIIb/IIIa) Inhibitors
  -Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,Glycoprotein IIb-IIIa (GPIIb/IIIa)
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA).
• 
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news